

MAB KEY INDICATORS. JULY 2019



First semester of 2019: the MAB keeps growing

The first half of 2019 has showed some positive data concerning the MAB companies:

- *Ibex MAB 15* index has closed this first semester with an annual revalorization of 25.39%.
- 124.487,671 securities have been negotiated with an effective of € 151.70 million, outweighing in more than 30% the figures reached in the same period of 2018.
- 5 companies were incorporated (4 within the REIT segment and 1 within the Growth Companies segment). However, during July, there will be new companies ready for being listed on the MAB.
- € 590 million have been raised through capital increases.

The abovementioned figures reinforce the good dynamic of the MAB, consolidating itself as a source of alternative financing for SMEs and REITs. [MORE +](#)



Success of AB-Biotics during its MAB journey

The Japanese multinational Kaneka Corporation (Kaneka) launched a public offer to acquire shares (opa) over 100% of AB-BIOTICS, with the purpose of buying 60.24% of the capital that it does not yet control and excluding this company from the MAB. Kaneka is offering a payment of €5 per share, valuating this company in more than €62 million. In this sense, AB-BIOTICS, which its capitalization barely exceed € 12 million at the time of its listing on the MAB in 2010, has multiplied by 5 times (x5) its value during the MAB' journey.

This transaction shows that the MAB, besides being a tool that helps boost the growth of their companies, gives to their issuers a notoriety and visibility contributing to have a great reward for their shareholders. [MORE +](#)



Kompuestos will soon debut within the MAB Growth Companies segment

The MAB Coordination and Admission Committee has sent a favourable report to the MAB Board of Directors in order to incorporate the company Plásticos Compuestos, S.A. ("Kompuestos") through a mixed transaction that will combine a capital increase with a disinvestment of some venture capital funds, which are currently minority shareholders.

Kompuestos, has a long track record in adding value to plastic by reducing CO² footprint in the manufacture of its components and it is leader in biodegradable compound for the plastics working on the recycling processes. The company aims is to play a principal role in the circular economy of plastic being sensitized therefore, to the environment. [MORE +](#)



BME & JLL, submit the REITs 2019 market report

On July 3, the "SOCIMIs. Estabilidad e inversión en el sector inmobiliario. Informe de Mercado 2019", was submitted in the Madrid Stock Exchange, by BME and the real estate consultant firm Jones Lang Lasalle ("JLL").

Jesús González, Managing-director of MAB, highlighted that, "in terms of financing, these vehicles have been very efficient for companies providing an attractive dividend yield to their investors". He also recalled that BME markets, both the Stock Exchange and the MAB, bring a reputation to the companies and pointed out that one of the most important challenge, among others, of this sector is to gain more confidence from retail investors. [MORE +](#)



Spring European Midcap Event: reunions with international investors

On June 18, took place the 15th edition of the "Spring European Midcap Event" sponsored by BME and GVC Gaesco with the organization of C&B Communication.

5 MAB companies and 5 of the Spanish Stock Exchange had the opportunity to introduce their at this event (AB-Biotics, ADL Bionatur Solutions, Atrys Health, Grenergy Renovables and Lleida.net) carried out more than 30 meeting with several European investors. [MORE +](#)

Latest analysis of MAB Companies

Company	Analyst	Date	Analysis
Greenalia	GVC Gaesco	05/2019	See analysis
AB-BIOTICS	Researchfy	06/2019	See analysis
Grenergy	MABIA	07/2018	See analysis



© Copyright 2019 BME.

We inform you that your contact information is stored in our systems and is handled in accordance with our [privacy policy](#). We keep your data for the sole purpose of sending you information related to our professional activity that we consider might be of your interest. Your contact information will be used exclusively for our own internal uses and will not be transferred to third parties. If you do not wish to receive our communications, please email us to infomab@grupobme.es to inform us. You may exercise in any time your access, rectification, erasure, restriction of processing, portability and objection rights, by writing to the Grupo BME's Data Protection Officer, Plaza de la Lealtad, 1, 28014 Madrid or by email to protecciondatos@grupobme.es. For any complaints you may contact the Agencia Española de Protección de Datos (www.aepd.es).